Sec Form 4 Filing - Pietrusko Robert @ VIROPHARMA INC - 2014-01-24

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Pietrusko Robert
2. Issuer Name and Ticker or Trading Symbol
VIROPHARMA INC [ VPHM]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
VP, Regulatory & Quality
(Last) (First) (Middle)
730 STOCKTON DRIVE
3. Date of Earliest Transaction (MM/DD/YY)
01/24/2014
(Street)
EXTON, PA19341
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/24/2014 U 70,877 D $ 50 0 D
Common Stock 01/24/2014 A 48,878 A 48,878 D
Common Stock 01/24/2014 D 48,878 D 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 15.08 01/24/2014 D 90,000 04/30/2008( 2 ) 04/30/2017 Common Stock 90,000 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 13.97 01/24/2014 D 14,000 06/15/2008( 2 ) 06/15/2017 Common Stock 14,000 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 9.96 01/24/2014 D 8,295 01/11/2009( 2 ) 01/11/2018 Common Stock 8,295 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 9.99 01/24/2014 D 9,975 06/13/2009( 2 ) 06/13/2018 Common Stock 9,975 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 13.5 01/24/2014 D 52,593 01/08/2010( 2 ) 01/08/2019 Common Stock 52,593 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 8.86 01/24/2014 D 13,714 01/07/2011( 2 ) 01/07/2020 Common Stock 13,714 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 11.31 01/24/2014 D 50,000 06/07/2011( 2 ) 06/07/2020 Common Stock 50,000 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 17.84 01/24/2014 D 40,261 01/05/2012( 2 ) 01/05/2021 Common Stock 40,261 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 17.98 01/24/2014 D 40,261 06/06/2012( 2 ) 06/06/2021 Common Stock 40,261 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 28.16 01/24/2014 D 27,265 01/05/2013( 2 ) 01/05/2022 Common Stock 27,265 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 23.37 01/24/2014 D 34,570 01/03/2014( 2 ) 01/03/2023 Common Stock 34,570 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 27.79 01/24/2014 D 32,516 06/10/2014( 2 ) 06/10/2023 Common Stock 32,516 ( 3 ) 0 D
Employee Stock Option (Right to Buy) $ 20.07 01/24/2014 D 35,723 06/04/2013( 2 ) 06/04/2022 Common Stock 35,723 ( 3 ) 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Pietrusko Robert
730 STOCKTON DRIVE
EXTON, PA19341
VP, Regulatory & Quality
Signatures
/s/ J. Peter Wolf, attorney-in-fact 01/28/2014
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Performance-based awards entitling the reporting person to shares of VPHM common stock upon the satisfaction of certain criteria were deemed satisfied in connection with the merger of ViroPharma Incorporated with and into Shire Pharmaceutical Holdings Ireland Limited, effective as of January 24, 2014 and canceled in exchange for an amount equal to $50 per share.
( 2 )The options vest in four equal annual installments beginning on the anniversary date from time of grant.
( 3 )This derivative security, regardless of whether otherwise previously vested, was canceled in connection with the merger of ViroPharma Incorporated with and into Shire Pharmaceutical Holdings Ireland Limited, effective as of January 24, 2014 in exchange for a cash payment representing the difference between the per-share exercise price of the stock option and $50.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.